News and Trends 18 Jan 2023 BioInvent receives funding for blood cancer treatments …antibody BI-1206, in non-Hodgkin’s lymphoma (NHL) and the anti-TNFR2 antibody BI-1808 in cutaneous T-cell lymphoma (CTCL). “We are delighted to conclude this agreement with the widely respected patient organization Leukemia… January 18, 2023 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2017 Novartis Scores Major Phase III Win with New Cardiovascular Drug …in one of the largest and longest-running Phase III trials in the company’s history. Canakinumab is a fully human monoclonal antibody that inhibits IL-1ß, a key cytokine in the inflammatory… June 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
Best in Biotech 4 Nov 2019 Top 10 Biotech Companies Leaving a Mark in Munich …biotech industry. MorphoSys Morphosys is one of just a few biotech companies in Europe valued at over €1Bn. Founded in 1992, the company specializes in the development of antibody treatments… November 4, 2019 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 8 May 2019 Top 10 Biotechs in Lausanne …discontinuing two phase III trials testing AC Immune’s lead antibody drug candidate as an Alzheimer’s treatment. However, the candidate is still in an ongoing phase II trial for the prevention… May 8, 2019 - 7 minutesmins - By David Cox Share WhatsApp Twitter Linkedin Email
Best in Biotech 15 Dec 2025 Keep an eye on these 15 biotech companies in 2026 …University in 2018, after which it gained the licensing rights to develop pharma giant Bayer’s then monoclonal antibody to address endometriosis. Dubbed HMI-115, the antibody blocks the binding of the hormone… December 15, 2025 - 21 minutesmins - Multiple Authors Share WhatsApp Twitter Linkedin Email
In Depth 2 Jan 2018 The Labiotech Dictionary of Important Biotech Terms …up to the immune system for destruction. The structure of an antibody, which allows it to bind dangerous pathogens, fight infection and stimulate an immune response. Some of Europe’s best… January 2, 2018 - 14 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Marengo advancing its lead TCR activator into clinic after FDA clearance …a bi-functional fusion antibody that deploys a mechanism of T cell activation that has demonstrated potent single agent activity in PD-1 refractory settings in preclinical studies. Marengo Therapeutics plans to… September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 6 Aug 2019 ADC Therapeutics and SOPHiA Genetics Team Up to Personalize Cancer Treatment …who will respond best to the drug. No financial details of the deal were disclosed. ADC Therapeutics’ drug is an antibody that is chemically joined to a molecule that kills… August 6, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Best in Biotech 21 Mar 2023 5 advancements in Down syndrome research over the past year …that inhibits plaque formation in the brain. The ACI-24.060 vaccine is designed to elicit an antibody response by the patient’s own immune system against pathological species of amyloid beta, according… March 21, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
Startup Scout 31 Jan 2020 This Cancer Immunotherapy Attacks the Sugar Coat of Tumor Cells …that are investigating glycans as a brand new target for cancer immunotherapies. CellmAbs’ lead candidate is an antibody drug designed to block aberrant glycans on cancer cells. Blocking these aberrant… January 31, 2020 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 3 May 2023 Positive study results: Lilly’s Alzheimer’s drug slows patients’ decline …decline, respectively. The incidence of amyloid-related imaging abnormalities (ARIA) was consistent with the TRAILBLAZER-ALZ phase 2 study. ARIA is observed with the amyloid plaque clearing antibody class of therapies and… May 3, 2023 - 8 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 17 Jan 2025 Are PD-1 and PD-L1 checkpoint inhibitors as good as we thought? …antibody targeting PD-L1 and VEGF-A had a 69.7% overall survival rate at 18 months. While the drug overtook Keytruda in the clinic, the question remains of whether the candidate will… January 17, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email